SXTP · 60 Degrees Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Knight Therapeutics Inc | ▼ Sell | Other | 78,803 Shares held | 7/28/2023 | View profile |
| MILLER TYRONE CFO | ▲ Buy | Grant | 26,370 Shares held | 1/17/2025 | View profile |
| DOW GEOFFREY S President and CEO | ▲ Buy | Open Market | 24,131 Shares held | 6/12/2026 | View profile |
| XU CHERYL Director | ▲ Buy | Open Market | 15,816 Shares held | 6/3/2025 | View profile |
| Allen Charles W Director | ▲ Buy | Option Exercise | 14,000 Shares held | 5/16/2024 | View profile |
| TOOVEY STEPHEN Director | ▲ Buy | Grant | 14,000 Shares held | 5/16/2024 | View profile |
| FIELD PAUL Director | ▲ Buy | Option Exercise | 14,000 Shares held | 5/16/2024 | View profile |
| Landon Kristen Chief Operating Officer | ▲ Buy | Grant | 4,540 Shares held | 1/17/2025 | View profile |
Transaction History
| DOW GEOFFREY S | ▲ Buy | Open Market | 7,350 | $10K | 6/12/2026 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 9,670 | $8K | 12/15/2025 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 3,613 | $3K | 12/11/2025 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 9,350 | $9K | 12/10/2025 |
| DOW GEOFFREY S | ▲ Buy | Grant | 7,201 | $10K | 9/12/2025 |
| DOW GEOFFREY S | ▲ Buy | Grant | 4,376 | $13K | 6/9/2025 |
| XU CHERYL | ▲ Buy | Open Market | 3,000 | $9K | 6/3/2025 |
| XU CHERYL | ▲ Buy | Open Market | 2,000 | $6K | 6/3/2025 |
| DOW GEOFFREY S | ▲ Buy | Grant | 14,394 | $0 | 1/17/2025 |
| MILLER TYRONE | ▲ Buy | Grant | 11,626 | $0 | 1/17/2025 |
| Landon Kristen | ▲ Buy | Grant | 4,540 | $0 | 1/17/2025 |
| XU CHERYL | ▲ Buy | Open Market | 2,000 | $3K | 12/16/2024 |
| XU CHERYL | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 |
| XU CHERYL | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 |
| XU CHERYL | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 |
| XU CHERYL | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 |
| XU CHERYL | ▲ Buy | Open Market | 2,500 | $5K | 12/12/2024 |
| XU CHERYL | ▲ Buy | Open Market | 2,500 | $5K | 12/12/2024 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 35,823 | $46K | 12/9/2024 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 20,579 | $25K | 12/6/2024 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 17,549 | $20K | 12/5/2024 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 3,500 | $3K | 11/21/2024 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 1,000 | $924 | 11/20/2024 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 2,500 | $2K | 11/19/2024 |
| XU CHERYL | ▲ Buy | Open Market | 5,000 | $9K | 8/27/2024 |
| XU CHERYL | ▲ Buy | Option Exercise | 2,000 | $446 | 5/16/2024 |
| FIELD PAUL | ▲ Buy | Option Exercise | 4,000 | $892 | 5/16/2024 |
| DOW GEOFFREY S | ▲ Buy | Option Exercise | 17,000 | $4K | 5/16/2024 |
| Allen Charles W | ▲ Buy | Option Exercise | 4,000 | $892 | 5/16/2024 |
| MILLER TYRONE | ▲ Buy | Grant | 15,000 | $3K | 5/16/2024 |
| TOOVEY STEPHEN | ▲ Buy | Grant | 4,000 | $892 | 5/16/2024 |
| DOW GEOFFREY S | ▲ Buy | Option Exercise | 68,000 | $18K | 4/12/2024 |
| MILLER TYRONE | ▲ Buy | Grant | 60,000 | $16K | 4/12/2024 |
| XU CHERYL | ▲ Buy | Option Exercise | 2,000 | — | 2/1/2024 |
| DOW GEOFFREY S | ▲ Buy | Open Market | 25,974 | $10K | 1/31/2024 |
| XU CHERYL | ▲ Buy | Open Market | 200,000 | $75K | 1/31/2024 |
| Knight Therapeutics Inc | ▼ Sell | Other | 2,162 | $0 | 7/28/2023 |
| Knight Therapeutics Inc | ▼ Sell | Other | 45,560 | $216K | 7/28/2023 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
SXTP to Release Babesiosis Interim Data and Appear on CNBC
60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.
SXTP to Release Babesiosis Interim Data and Appear on CNBC. 60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.